FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/09/028006 [Registered on: 23/09/2020] Trial Registered Prospectively
Last Modified On: 16/09/2020
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Comparative effect of fresh and dry Giloy (Guduchi) in the management of diabetes  
Scientific Title of Study   Efficacy of Aardra and Shushka Guduchi [Tinospora cordifolia (Willd) Miers] in the management of Madhumeha (Type-II DM): A Comparative open label Randomized controlled clinical trial 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Niranjan Ram 
Designation  Post graduate scholar - M.D. Ayu 
Affiliation  All India Institute of Ayurveda 
Address  Department of Dravyaguna, Room No- 219, 211 2nd floor, Academic block All India Institute of Ayurveda Gautam Puri Sarita vihar New Delhi

New Delhi
DELHI
110076
India 
Phone  7978796914  
Fax    
Email  vaidyaniranjanram@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof Dr Tanuja Manoj Nesari 
Designation  Professor -cum- Director 
Affiliation  All India Institute of Ayurveda 
Address  Department of Dravyaguna, Room No- 218 2nd floor, Academic block All India Institute of Ayurveda Gautam Puri Sarita vihar New Delhi

South
DELHI
110076
India 
Phone  9958817145  
Fax    
Email  tnesari@hotmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Niranjan Ram 
Designation  Post graduate scholar - M.D. Ayu 
Affiliation  All India Institute of Ayurveda 
Address  Department of Dravyaguna, Room No- 219, 211 2nd floor, Academic block All India Institute of Ayurveda Gautam Puri Sarita vihar New Delhi

South
DELHI
110076
India 
Phone  07978796914  
Fax    
Email  vaidyaniranjanram@gmail.com  
 
Source of Monetary or Material Support  
All India Institute of Ayurveda Gautam Puri, Sarita vihar New Delhi -110076 
 
Primary Sponsor  
Name  All India Institute of Ayurveda 
Address  Gautam Puri Sarita vihar New Delhi 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Niranjan Ram  All India Institute of Ayurveda  Department of Dravyaguna, 2nd floor, Academic block All India Institute of Ayurveda, Gautam Puri, Sarita Vihar-110076
South
DELHI 
07978796914

vaidyaniranjanram@gmail.com 
Prof Dr Tanuja Manoj Nesari   All India Institute of Ayurveda  Department of Dravyaguna, 2nd floor , Academic block All India Institute of Ayurveda, Gautam Puri, Sarita Vihar-110076
South
DELHI 
9958817145

tnesari@hotmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC-All India Institute of Ayurveda  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  , (1) ICD-10 Condition: E118||Type 2 diabetes mellitus with unspecified complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Glimepiride (1mg)  Glimepiride (1mg) tablets, 15 minutes before breakfast, once a day or titrate as per blood glucose level 
Intervention  TCa (Guduchi Ghan tablet prepared from fresh Guduchi)  TCa tablet - 500 mg twice a day after breakfast and supper, orally with luke warm water, daily for a period of 3 months 
Intervention  TCs (Guduchi Ghan tablet prepared from dry Guduchi)  TCs tablet- 500 mg twice a day after breakfast and supper,after breakfast and supper, orally with luke warm water, daily for a period of 3 months 
 
Inclusion Criteria  
Age From  25.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1. Recently diagnosed (less than 1 year of diabetic history) cases of Type-2 DM and not taking any antidiabetic drug/Insulin since 2 months

2. Including both Pre-diabetes and diabetes cases

Fasting Blood Sugar (FBS) ranges between 100 to 125 mg/dl in pre-diabetes and greater than 126 mg/dl to less than equal to 200 mg/dl in diabetes cases.

Post Prandial Blood Sugar (PPBS) ranges between
140 to 199 mg/dl in Pre-diabetes and greater than 200 mg/dl to less than equal to 350 mg/dl in diabetes cases.

HbA1c ranges between 5.7 % to 6.4 % in Pre-diabetes and greater than equal to 6.5 % to less than equal to 8 % in diabetes cases.

3. Presence of urine sugar
4. Frequency of urination 7 to 10 times per 24 hours and quantity and quantity greater than equal to 2500 ml

5. Accidentally diagnosed cases of Type-2 DM who visit the hospital for other complaints 
 
ExclusionCriteria 
Details  1. Cardiovascular disorder with Type-2 DM
2. Malignant and accelerated Hypertensive
3. Pregnant woman and planning to be pregnant within 6 months
4. Lactating mother
5. Secondary Diabetes Mellitus
6. Patients undergoing regular treatment for diabetes or any other severe illness
7. CNS Disorder e.g. Encephalopathy
8. Subjects already suffering from the complications of Diabetes (Diabetes Nephropathy, Diabetic retinopathy, Diabetic Neuropathy etc.)
9. Poorly controlled Glycemic status (HbA1c greater than 8%)
10. Concurrent serious hepatic dysfunction (AST or ALT greater than 3 times of upper normal limit)
11. Subjects on steroids, oral contraceptives or estrogen replacement therapy
12. Alcoholics and/or drug abusers
13. H/O hypersensitivity to any trial drug
14. Hypothyroidism or hyperthyroidism
15. Patients on vitamin B supplementation
16. Patients under other clinical trials for more than 12 weeks
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   An Open list of random numbers 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To access clinically the comparative anti-diabetic activity of Aardra (TCa) and Shushka (TCs) Guduchi by assessing the blood glucose level and HbA1c level  1. Blood Glucose level - 0th day, 15 th day, 30th day, 45 th day, 60 th day, 75 th day, 90th day

2. HbA1c level - 0th day and 90th day 
 
Secondary Outcome  
Outcome  TimePoints 
1. Analytical study (HPLC, HPTLC) of TCa and TCs

2. Quality of Life assessment. 
HPLC and HPTLC - 0th

Quality of Life - 0 and 90 th day 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   15/10/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   The thesis work will be published in reputed journal after completion. 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   INTRODUCTION -

Diabetes mellitus is a sovereign disease considered as one of the arch-enemies of mankind, resulting due to faulty diet and lifestyle. It is a group of metabolic disorders characterized by hyperglycemia caused by an absolute or relative deficiency of Insulin There are 3 main types of Diabetes mellitus - 1) Type-1 DM 2) Type-2 DM 3) Gestational DM. In Ayurveda texts, the characteristic features of "Madhumeha" shows remarked resemblance with the syndrome of Diabetes Mellitus -2 (Type-2 DM). Madhumeha  is a tridoshaja vyadhi but our ancient scholars mainly emphasized on vitiation of Kapha dosha, Medodusthi and Meda dhatwagni mandya. For disintegrating the pathogenesis, there must be a single drug or a formulation at the level of dhatwagni and counteracting Kapha dosha and Meda dhatu

Guduchi (Tinospora cordifolia) is having Katu-Tikta-Kashaya Rasa, Laghu Guna, Ushna veerya and Tridoshaghna activity which may help in the disintegration of the pathogenesis of Madhumeha. Again in Madhumeha, there is Ojakshyaya (Oja is equivalent to Bala) and Guduchi is having the property of Balya and Rasayana. Regarding the form in which Guduchi is used, classics of Ayurveda have advised using it in "Ardra" (fresh) form but in day to day practice unfortunately it is used in the "Shushka" form. Further, a few works have been reported towards evaluating the efficacy of the classically mentioned use of "Ardra Guduchi". Therefore, a clinical study to compare the anti-diabetic effect of Tinospora cordifolia - ardra (TCaand Tinospora cordifolia - shushka (TCsis planned

OBJECTIVES OF RESEARCH - 

1. Primary objective - To assess clinically the comparative anti-diabetic activity of Ardra (TCa) and Shushka (TCs) Guduchi.
2. Secondary objectives - * Analytical study (HPLC, HPTLC) of TCa and TCs.
                                         * Quality of Life (QOL) Assessment

METHODOLOGY - 

1. Drug Identification - Certification from taxonomist and Dravyaguna specialist will be taken and a voucher specimen will be preserved.

2. Drug Analysis - Analysis of TCa and TCs in HPLC and HPTLC method.

3. Drug Preparation - The drugs are prepared in the college pharmacy or procured from any reputed pharmacy as suitable.

4. Study Design- Three Armed Randomised Standard Controlled Trial.

5. Sample Size = Total 60 ( 20 in each group)

6. Group - A  (TCa + Lifestyle modification) - TCa Ghan (aqueous solid extract) tablets, at a dose of 500 mg twice a day orally after breakfast and supper with lukewarm water.

7. Group - B (TCs + Lifestyle modification) - TCs Ghan tablets, at a dose of 500 mg twice a day orally after breakfast and supper with lukewarm water.

8. Group - C (Standard control) (Glimepiride + Lifestyle modification + Placebo capsules of wheat powder) - Glimepiride (1mg) tablets and 1 placebo capsule once a day (or titrate as per blood glucose level) orally 15 minutes before breakfast with water.

9. Duration - 3 months 

10. Purpose of the trial - The purpose of the trial is the same as the primary objective of the research i.e. to evaluate clinically the comparative antidiabetic activity of Ardra & Shushka Guduchi (TCa and TCs).

11. Findings if any - As the patient recruitment is not started yet henceforth the findings are going to be evaluated after completion of the study.

12. Publication details - After completion of the thesis work, the study will be published in peer-reviewed journals.

   





























 
Close